FibroBiologics (FBLG) Accumulated Depreciation (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Accumulated Depreciation of $580000.0 for Q2 2026, up 82.97% year-over-year from $317000.0 in Q2 2025, and up 12.84% on a QoQ basis from $514000.0 in Q1 2026.
FibroBiologics (FBLG) Accumulated Depreciation (2023 - 2026) Analysis & Trends
FibroBiologics has reported Accumulated Depreciation for 4 years, with the latest figure at $580000.0 in Q2 2026.
- Accumulated Depreciation for Q2 2026 came in at $580000.0, up 82.97% year-over-year; the trailing twelve-month figure through Jun 2026 was $580000.0 (up 82.97% YoY), and the FY2025 annual result was $448000.0, up 119.61% from the prior year.
- Accumulated Depreciation improved to $580000.0 in Q2 2026, from $514000.0 in the prior quarter.
- Over five years, Accumulated Depreciation peaked at $580000.0 in Q2 2026 and troughed at $47000.0 in Q4 2023.
- A 4-year average of $302500.0 and a median of $287000.0 in 2025 frame the typical range for Accumulated Depreciation.
- The widest annual swing landed in 2024, when Accumulated Depreciation surged 334.04%; it then jumped 82.97% in 2026.
- A 4-year view of Accumulated Depreciation shows it stood at $47000.0 in 2023, then surged by 334.04% to $204000.0 in 2024, then surged by 119.61% to $448000.0 in 2025, then increased by 29.46% to $580000.0 in 2026.
- Per Business Quant data, the three most recent Accumulated Depreciation figures were $580000.0 in Q2 2026, $514000.0 in Q1 2026, and $448000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 580,000.00 |
| Mar 31, 2026 | 514,000.00 |
| Dec 31, 2025 | 448,000.00 |
| Sep 30, 2025 | 382,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | 257,000.00 |
| Dec 31, 2024 | 204,000.00 |
| Sep 30, 2024 | 157,000.00 |
| Jun 30, 2024 | 119,000.00 |
| Dec 31, 2023 | 47,000.00 |